Status:

COMPLETED

Intravitreous Bevacizumab and Standard Metabolic Control for Diabetic Macular Edema - A Contrast Sensitivity Study

Lead Sponsor:

University of Sao Paulo

Conditions:

Diabetic Macular Edema

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

To evaluate the effects on contrast sensitivity (CS) measurements of intravitreal bevacizumab injections associated with standard metabolic control in eyes with diabetic macular edema (DME) associated...

Detailed Description

Prospective, randomized, masked and interventional study. Patients with diabetes mellitus (DM) 2, glycated hemoglobin (HbA1c) less than 11% and previously treated macular edema three months before wil...

Eligibility Criteria

Inclusion

  • Age at least 18 years old, of both genders;
  • Patients with diabetes mellitus type I or type II;
  • Macular edema presence of clinically significant diabetic in their mixed or diffuse;
  • Visual acuity worse than 20/40 corrected (\< 68 letters ETDRS)
  • Glycated hemoglobin ≤ 11%;
  • Systolic and diastolic blood pressure \< 170 and \< 100 mmHg, respectively;
  • Women not pregnant;
  • Free and informed consent term signed the screening visit;
  • Ability to adhere to the visits.

Exclusion

  • Failure to comply with any of the inclusion criteria;
  • Treatment for DME within the prior 3 months;
  • Vitreoretinal traction within 1 disc diameter (DD) of the fovea, clinically confirmed or with OCT;
  • Atrophy or fibrosis surrounding the fovea;
  • Any level of cataract;
  • Vitreous hemorrhage or any opacity means;
  • Eye disease related to diabetic retinopathy that can derail the central vision (eg Age Macula Degeneration, chorioretinitis scar, ...)
  • Best-corrected visual acuity to 20/40 (\> 68 letters ETDRS)
  • Inability to understand the treatment and the term of consent;
  • Debilitating systemic disorders that preclude the patient's admission to the study, according to the clinical judgment of the investigator;

Key Trial Info

Start Date :

February 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 1 2013

Estimated Enrollment :

41 Patients enrolled

Trial Details

Trial ID

NCT02308644

Start Date

February 1 2009

End Date

February 1 2013

Last Update

December 4 2014

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Sao Paulo

São Paulo, São Paulo, Brazil, 05403-000